Boer Daniel Anton De Purchases 150,000 Shares of ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) CEO Boer Daniel Anton De acquired 150,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were purchased at an average cost of $1.59 per share, for a total transaction of $238,500.00. Following the acquisition, the chief executive officer owned 150,000 shares of the company’s stock, valued at approximately $238,500. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

ProQR Therapeutics Stock Performance

ProQR Therapeutics stock opened at $1.76 on Friday. ProQR Therapeutics N.V. has a fifty-two week low of $1.33 and a fifty-two week high of $3.10. The company has a market capitalization of $185.43 million, a P/E ratio of -3.52 and a beta of 0.04. The stock has a 50-day simple moving average of $1.61 and a 200-day simple moving average of $1.68.

ProQR Therapeutics (NASDAQ:PRQR) last announced its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.15). The firm had revenue of $2.35 million during the quarter, compared to analysts’ expectations of $5.19 million. ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%. As a group, analysts forecast that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on PRQR shares. JonesTrading cut their target price on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Chardan Capital decreased their price target on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, June 26th. Oppenheimer started coverage on shares of ProQR Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price objective on the stock. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a research note on Wednesday, May 27th. Finally, Weiss Ratings cut shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.33.

Institutional Trading of ProQR Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in PRQR. Aberdeen Group plc lifted its holdings in shares of ProQR Therapeutics by 28.4% in the 4th quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock valued at $5,960,000 after buying an additional 651,853 shares during the period. Ikarian Capital LLC raised its position in ProQR Therapeutics by 67.2% in the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock worth $3,014,000 after acquiring an additional 600,000 shares in the last quarter. Privium Fund Management B.V. raised its position in ProQR Therapeutics by 7.2% in the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock worth $10,823,000 after acquiring an additional 359,475 shares in the last quarter. Citadel Advisors LLC lifted its holdings in ProQR Therapeutics by 73.2% in the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock valued at $1,399,000 after acquiring an additional 277,749 shares during the period. Finally, Millennium Management LLC lifted its holdings in ProQR Therapeutics by 80.8% in the fourth quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock valued at $879,000 after acquiring an additional 194,369 shares during the period. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.